Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

Wadden, Thomas A.; Hollander, Priscilla; Klein, Samuel; Niswender, Kevin D.; Woo, V.; Hale, Paula M; Aronne, Louis J.

doi:10.1038/ijo.2013.120

Cited by 637 publications

(670 citation statements)

References 31 publications

Supporting

Mentioning

573

Contrasting

Unclassified

Order By: Relevance

“…The exaggerated release of gut hormones post RYGB has been implicated as a potential mediator of the observed changes in food preferences and weight loss. Their anorexigenic properties are already being exploited to treat obesity and gut hormones analogues are showing great promise (72)(73)(74)(75) , for example, Liraglutide 3 mg, a GLP-1 agonist, has recently been approved as an antiobesity drug in the USA and Europe. Perhaps the key to a 'medical bypass' relies on successfully mimicking the hormonal milieu of RYGB with the additive or even synergistic effects of combination gut hormones.…”

Section: Resultsmentioning

confidence: 99%

Food preferences and underlying mechanisms after bariatric surgery

Behary

Miras

2015

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Bariatric surgery leads to significant long-term weight loss, particularly Roux-en-Y gastric bypass (RYGB). The mechanisms underlying weight loss have not been fully uncovered. The aim of this review is to explore the changes in food preferences, as a novel mechanism contributing to weight loss, and also focus on the underlying processes modulating eating behaviour after bariatric surgery. Patients after gastric bypass are less hungry and prefer healthier food options. They develop an increased acuity to sweet taste, which is perceived as more intense. The appeal of sweet fatty food decreases, with functional MRI studies showing a corresponding reduction in activation of the brain reward centres to high-energy food cues. Patients experiencing post-ingestive symptoms with sweet and fatty food develop conditioned aversive behaviours towards the triggers. Gut hormones are elevated in RYGB and have the potential to influence the taste system and food hedonics. Current evidence supports a beneficial switch in food preferences after RYGB. Changes within the sensory and reward domain of taste and the development of post-ingestive symptoms appear to be implicated. Gut hormones may be the mediators of these alterations and therefore exploiting this property might prove beneficial for designing future obesity treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Food preferences and underlying mechanisms after bariatric surgery

Behary

Miras

2015

Proc. Nutr. Soc.

View full text Add to dashboard Cite

show abstract

“…Weight loss in a 20-week trial in non-obese patients was 4.4 kg higher than in the placebo group [26]. A greater benefit (5.9 kg) was reported for a trial of weight maintenance following a 12-week low-calorie diet [27]. The mechanism of action of liraglutide endows it with anti-diabetic activity beyond what might be predicted from its anti-obesity activity.…”

Section: Recent Approvalsmentioning

confidence: 93%

Horizons in the Pharmacotherapy of Obesity

Arch

2015

Curr Obes Rep

View full text Add to dashboard Cite

Abstract:Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT2C agonist lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators' caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy.3

show abstract

“…Liraglutide is well known for weight loss benefits and weight loss maintenance. [3][4][5] Clinical trials demonstrated a weight loss of 3.7-8 kg after a 2-year period of liraglutide 3 mg per day and a weight loss of 1.3-4.7 kg using 2.4 or 3.0 mg daily in respective studies. 3 Weight loss benefits were evident when liraglutide was combined with metformin and a sulphonylurea.…”

Section: Discussionmentioning

confidence: 99%

Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes

2016

View full text Add to dashboard Cite

IntroductionObesity and type 2 diabetes are commonly seen together in current clinical practice. Morbid obesity and poorly controlled diabetes is often a therapeutic challenge. Management ideally needs to target insulin resistance and hormonal control mechanisms. When subcutaneous insulin is used in patients with obesity and type 2 diabetes, it exacerbates weight gain and thus a vicious cycle of worsening insulin resistance requires additional management strategies.We report a case of exaggerated weight reduction with combination therapy of liraglutide and dapagliflozin. The patient achieved a loss in excess body weight (EBW) of 73.5 kg or 40.3% and a reduction in HbA1c from 83 mmol/mol (9.7%) to 36 mmol/mol (5.4%) in response to the combination therapy of oral dapagliflozin with subcutaneous liraglutide and concurrent discontinuation of subcutaneous insulin.

show abstract

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

Cited by 637 publications

References 31 publications

Food preferences and underlying mechanisms after bariatric surgery

Food preferences and underlying mechanisms after bariatric surgery

Horizons in the Pharmacotherapy of Obesity

Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes

Contact Info

Product

Resources

About